SEC filings and other documents

Net loss increased to $16.7 million, with urgent need for new capital to sustain operations.

Net loss increased, cash runway is limited, and significant new capital is required for commercialization.

Precision-guided nerve ablation platform delivers durable pain relief and targets a $100B market.

Net loss increased to $7.5M for the quarter, with cash runway into Q3 2026 and further funding required.

Net loss increased, cash runway limited, and further capital is required for continued operations.

Amendment adds executive, compensation, and governance details, with strong risk controls and oversight.

Net loss narrowed year-over-year; cash raised via offering, but going concern risks remain.

Net loss narrowed, but cash will only fund operations into Q2 2025; major funding needed.

Net loss increased to $2.7 million, with cash runway into Q2 2025 and urgent need for new funding.